Adendum: Otsuka USA
It was wrongly stated that Otsuka Pharmaceuticals has reorganized its US operations into a single unit (Marketletter January 29). In fact, the company has asked us to point out, Otsuka Pharmaceutical Development & Commercialization (OPDC) was formed by merging together the Otsuka Maryland Research Institute with the Global Development & Commercialization, a division of Otsuka America Pharmaceutical, Inc. OPDC joins the existing Otsuka America Pharmaceutical (OAPI), and Otsuka Maryland Medicinal Laboratories (OMML) both of which have been in existence in the USA for 18 years and 22 years, respectively (OMML was previously known as Maryland Research Laboratories; it was renamed OMML in 2003).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze